November 11, 2019

 ADD TOPIC TO EMAIL ALERTSPlayMuteLoaded: 87.70%Remaining Time -1:10SharePicture-in-PictureFullscreen

SAN FRANCISCO — In the OPTIC trial, patients with wet age-related macular degeneration who were treated with ADVM-022, an intravitreal gene therapy, did not require additional injections following treatment, according to a presenter at the American Academy of Ophthalmology annual meeting.

“A one and done gene therapy treatment is thus on the horizon and the potential for patients to not get those injections or not need those injections is definitely possible,” Szilard Kiss, MD, director of the Retina Service at Weill Cornell Medical Center, told Ocular Surgery News. – by Alaina Tedesco

Reference: Kiss S. 24-week results of phase 1 study of intravitreal gene therapy with ADVM-022 for neovascular AMD (OPTIC Trial). Presented at: American Academy of Ophthalmology annual meeting; Oct. 11-15, 2019; San Francisco.

Disclosure: Kiss reports being a consultant for Adverum, RegenxBio and Spark Therapeutics.